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Abstract: The exclusion of collateral ventilation (CV) and other factors affect the clinical 
success of endoscopic lung volume reduction (ELVR). However, despite its benefits, the 
outcome of ELVR remains difficult to predict. We investigated whether clinical success could 
be predicted by emphysema distribution assessed by computed tomography scan and baseline 
perfusion assessed by perfusion scintigraphy. Data from 57 patients with no CV in the target 
lobe (TL) were retrospectively analyzed after ELVR with valves. Pulmonary function tests 
(PFT), St George’s Respiratory Questionnaire (SGRQ), and 6-minute walk tests (6MWT) 
were performed on patients at baseline. The sample was grouped into high and low levels at 
the median of TL perfusion, ipsilateral nontarget lobe (INL) perfusion, and heterogeneity index 
(HI). These groups were analyzed for association with changes in outcome parameters from 
baseline to 3 months follow-up. Compared to baseline, patients showed significant improvements 
in PFT, SGRQ, and 6MWT (all P#0.001). TL perfusion was not associated with changes in the 
outcome. High INL perfusion was significantly associated with increases in 6MWT (P=0.014), 
and high HI was associated with increases in forced expiratory volume in 1 second (FEV
1
), 
(P=0.012). Likewise, there were significant correlations for INL perfusion and improvement 
of 6MWT (r=0.35, P=0.03) and for HI and improvement in FEV
1
 (r=0.45, P=0.001). This 
study reveals new attributes that associate with positive outcomes for patient selection prior to 
ELVR. Patients with high perfusions in INL demonstrated greater improvements in 6MWT, 
while patients with high HI were more likely to respond in FEV
1
.
Keywords: endoscopic lung volume reduction, COPD, valves, lung perfusion, emphysema 
distribution
Introduction
Endoscopic lung volume reduction (ELVR) with valves has been shown to improve 
lung function, exercise capacity, and quality of life in selected patients with severe 
lung emphysema.1–5 However, a large spectrum of clinical treatment responses has 
been observed, emphasizing the importance of patient selection prior to treatment.1 
Although the selection criteria for ELVR have recently improved, it remains a chal-
lenge for clinicians to identify those patients with the highest benefit–risk ratio.
The development of target lobe (TL) atelectasis is an important surrogate marker for 
clinical response.6,7 A TL volume reduction of 350 mL has been defined in several stud-
ies as indicative of significant lobe volume reduction associated with clinical benefits.8 
Recent post hoc analyses of large studies have identified complete lobular occlusion by 
valves and the exclusion of interlobar collateral ventilation (CV) as important predic-
tive factors.9–12 CV is defined as the ventilation between lobes that bypasses the normal 
airways.13 The importance of CV to the outcome of ELVR was recently demonstrated by 
a prospective sham-controlled randomized trial.2 It has become clinical routine to assess 
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interlobar CV by the analysis of fissure integrity from com-
puted tomography (CT) scans or by endobronchial in vivo 
measurement using the Chartis system. Both techniques have 
shown comparable accuracies.14–16
CT scans and ventilation/perfusion scintigraphy are rou-
tinely performed to better characterize COPD lungs prior to 
ELVR.1,16–18 While emphysema heterogeneity is widely used 
as a selection criterion for ELVR treatment, its role is currently 
under discussion: in the original North American VENT study 
cohort, heterogeneous emphysema distribution predicted 
improvement in the 6-minute walk test (6MWT) and in the 
forced expiratory volume in 1 second (FEV
1
).1 In contrast, the 
European VENT cohort and two recent studies did not find 
a difference in outcome parameters for homogenous or het-
erogeneous emphysema distribution.6,9,16
Low perfusion of the upper lobes, as assessed by 
ventilation/perfusion scans, was shown to associate with 
less mortality19 following lung volume reduction surgery, 
the surgical equivalent of ELVR. When lung perfusion was 
taken into consideration for ELVR, a recent study suggested 
that patients with low perfusion of the TL demonstrated more 
improvement in exercise capacity after ELVR than patients 
with high perfusion in the TL.17
In the context that CT and ventilation/perfusion scans 
are important tools for assessing COPD patients prior to 
ELVR, we investigated whether emphysema distribution and 
baseline perfusion of lung lobes help to predict the clinical 
outcome of ELVR with valves.
Materials and methods
Patients
We retrospectively analyzed 57 patients treated with ELVR 
between September 2011 and July 2014 at the Charité Hospital 
in Berlin, Germany. The study design was approved by the 
ethics committee of the Charité Universitätsmedizin Berlin 
(EA1/064/12). All patients provided written informed consent. 
Inclusion criteria for ELVR were age over 40 years, diagnosis 
of COPD with FEV
1
 below 45% predicted, and nonsmoker 
status for at least 3 months proven by Hbco below 2.0%. No 
ELVR was performed on patients with signs of an infection, 
myocardial infarction in the past 6 months, and severe comor-
bidities (malignant disease, severe bronchiectasis, asthma, 
pulmonary hypertension, and lung fibrosis). For the retrospec-
tive analysis, we further excluded patients with α1 antitrypsin 
deficiency, CV in the TL as detected by the Chartis system, 
and implantation of valves in the middle lobe, and missing 
follow-up examination.
Prior to ELVR, all patients underwent pulmonary function 
tests (PFT) for FEV
1
, vital capacity (VC), residual volume 
(RV), diffusing capacity of the lung for carbon monoxide 
(corrected for lung volume) (Kco), as well as 6MWT and 
St George’s Respiratory Questionnaire (SGRQ), which 
ranges from 0 to 100, with higher scores associating with 
lower quality of life. Low-dose CT under deep inspiration and 
ventilation/perfusion scintigraphy was performed on patients 
to assess emphysema distribution and lobe perfusion in the 
lung. Patients without contraindications for ELVR from these 
evaluations further received a Chartis assessment (Pulmonx, 
Redwood City, CA, USA) to exclude possible CV. A team 
of pneumologists and radiologists defined the primary and 
alternative TL according to the most emphysematous lobes 
in the CT scan. If multiple lobes showed a high degree of 
emphysema, lobes with less perfusion in the scintigraphy 
were preferred. The perfusion of the ipsilateral adjacent lobe 
was not considered for TL selection. Finally, the primary or 
alternative TL was chosen for treatment if no CV was detected 
in the Chartis assessment. The patients were hospitalized for 
the ELVR valve treatment. Endobronchial one-way silicone 
valves (Zephyr, Pulmonx) were implanted in the bronchus 
via a flexible delivery catheter, and the TL was completely 
occluded with valves. Follow-up assessment of the patients 
3 months later included another CT scan, PFT, 6MWT, and 
SGRQ. The data were compared to baseline values.
Because left lungs were found to be more frequently 
negative for CV, ELVR was more often performed in the 
left lung: right upper lobe (RUL; n=7), right lower lobe 
(RLL; n=4), left upper lobe (LUL; n=13), and left lower 
lobe (LLL; n=33).
Perfusion scintigraphy
Lung perfusion was assessed using a combined single-photon 
emission computed tomography (SPECT) and CT system. 
Technical details of the procedure are available in the supple-
mentary material. Only the posterior-to-anterior planar views 
were analyzed due to the lack of software-based quantifica-
tion tools for SPECT. Each lung perfusion scintigram was 
split craniocaudally into three regions to quantify the distribu-
tion of the tracer in the lungs. The perfusion was calculated 
as the percentage of tracer activity in the upper, middle, and 
lower regions of the right and left lung. The upper region 
perfusion was used as a surrogate for upper lobe perfusion, 
and the lower region perfusion was used as a surrogate for 
lower lobe perfusion, as recently described.17 The perfusion 
of the middle region was not considered for further analyses. 
Figure 1 shows examples of different perfusion scintigrams. 
Three patients had no ventilation and perfusion scintigraphies 
and were excluded from the analyses of TL and ipsilateral 
nontarget lobe (INL) perfusion.
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low-dose CT scans
Patients underwent a CT scan for TL selection and emphy-
sema evaluation at baseline and 3 months after endoscopic 
valve implantation as follow-up. All patients were examined 
using the same CT scanner (General Electric LightSpeed 
Ultra 8, General Electric Inc, Milwaukee, WI, USA) and 
the same scanning protocol (continuous helical scan of the 
whole lung in deep inspiratory breath hold, no intravenous 
contrast agent, primary slice thickness 1.25 mm, 100 kV 
voltage, and 100 mA current). Reconstruction of the raw CT 
data was performed using a “standard” (soft tissue) kernel. 
Quantitative analysis of lung parenchyma from CT data was 
performed semiautomatically using the MeVisPULMO3D 
software (v3.42, Fraunhofer MeVis, Bremen, Germany). The 
software was able to evaluate the distribution of emphysema 
by calculating the pixel index, defined as the ratio of lung 
voxels with a density ,-950 Hounsfield units to the total 
number of voxels in the lung per lobe, which also is the 
emphysema score per lobe. The heterogeneity index (HI) was 
defined as the difference in emphysema score between TL 
and ipsilateral nontarget upper or lower lobe, as previously 
reported.1,9,20 The middle lobe was not considered for further 
analyses. Figure 1 shows examples of different emphysema 
distributions. TL volume reduction was calculated as the 
difference between TL volume at baseline and TL volume at 
follow-up. Three patients had no baseline CT data and were 
excluded from the heterogeneity analysis.
statistics
First, patients were grouped into high and low levels at 1) 
the median of TL perfusion (Table S1), 2) the median of 
INL perfusion (Table 1), and 3) the median of HI (Table 2). 
Figure 1 Quantification of baseline CT and perfusion scintigrams prior to ELVR with valves. 
Notes: CT scans on inspiration were assessed by MeVisPUlMO3D for segmentation of emphysema clusters in the lung. The brown colored areas show pixels of ,-950 
Hounsfield units, suggestive of emphysema. The numbers in the CT indicate the percentage of emphysema in each lung lobe relative to the total number of voxels in the 
respective lobe. The HI is defined as the difference in emphysema score between TL and INL. A high HI indicates a more heterogeneous emphysema. The numbers in the 
perfusion scintigrams indicate the tracer activity in the respective region as percentage of both lungs, calculated for the geometric mean. The patients were grouped into 
high and low levels of the medians of hI (12.2%) and Inl perfusion (14.7%) among all patients. The red circle marks the Tl for elVr. Views are from anterior to posterior. 
(A) example of a patient with high hI (13%) and high Inl perfusion (18%). (B) example of a patient with high hI (30%) and low Inl perfusion (10%). (C) example of a patient 
with low hI (5%) and high Inl perfusion (15%). (D) example of a patient with low hI (8%) and low Inl perfusion (3%).
Abbreviations: CT, computed tomograms; elVr, endoscopic lung volume reduction; FeV1, forced expiratory volume in 1 second; 6MWT, 6-minute walk test; hI, 
heterogeneity index; Tl, target lobe; Inl, ipsilateral nontarget lobe.
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Between these groups, the changes in the outcome parameters 
(PFT, SGRQ, and 6MWT) were compared. Next, correlations 
were calculated between TL perfusion, INL perfusion, HI, 
and the changes in the outcome parameters. The chi-square 
test and the Fisher’s exact test were used for the statistical 
analysis of categorical variables. The Mann–Whitney U-test 
was used for continuous variables. The Wilcoxon test was 
used for paired samples, eg, changes in the outcome param-
eters from baseline to follow-up. Correlations were assessed 
by Pearson’s correlation coefficient and Student’s t-test. 
All tests were two-tailed. SPSS Statistics Version 22 (IBM 
Corporation, Armonk, NY, USA) was used for all analy-
ses. The data are presented as mean ± standard deviation. 
A P-value ,0.05 was considered statistically significant.
Results
Fifty-seven patients, assessed to be negative for CV by Chartis, 
were treated with endobronchial valves. Compared to baseline, 
all patients demonstrated at follow-up a mean volume reduc-
tion in the TL of 1,184±577 mL, an improvement in FEV
1
 of 
23.8%±24.9%, RV of -8.0%±17.3%, VC of 15.9%±23.2%, 
SGRQ of -10.1±14.0 points, and 6MWT of 34.6±62.3 m (all 
P#0.001, Figure 2). Further details are listed in Table S2.
The baseline characteristics and outcome data for TL per-
fusion, INL perfusion, and HI groups are listed in Tables 1, 2 
and S1. The TL perfusion ranged from 1.8% to 19.9% with 
a median of 8.11% (Table S1), the INL perfusion ranged 
from 3.4% to 25.7% with a median of 14.7% (Table 1), and 
HI ranged from 0.6% to 32.8% with a median of 12.2% 
(Table 2). The median perfusion was lowest in LLL (8.8%), 
compared to LUL (14.7%), RLL (13.4%), and RUL (13.4%). 
With respect to HI, 27 patients were categorized in the 
homogeneous emphysema group and 27 patients were in the 
heterogeneous emphysema group (cutoff 12.2%).
There were no significant correlations between TL per-
fusion and HI as well as INL perfusion and HI (Figure 3). 
Table 1 Patient baseline characteristics and clinical outcome with respect to baseline Inl perfusion
Parameters Below median INL perfusion (,14.7%) Above median INL perfusion (14.7%) P-value
n 27 27
Baseline Inl perfusion 11.1±3.2 17.9±3.2 0.001
sex, n, (male/female) 19/8 12/15 ns
age (yr) 67.8±5.7 68.5±5.5 ns
BMI (kg/m2) 26.9±4.4 23.7±4.9 0.023
smoking history (pack-yr) 49.7±18.2 46.5±23.8 ns
hI ,12.2% 12 13 ns
hI $12.2% 13 13
Treatment site 0.002
rUl 3 4
rll 1 3
lUl 12 1
lll 11 19
Baseline FeV1 (% pred) 27.4±7.4 25.9±6.4 ns
Baseline VC (% pred) 67.2±13.7 61.7±12.4 ns
Baseline rV (% pred) 212±44 222±31 ns
Baseline TlC (% pred) 121±16 123±11 ns
Baseline Kco (% pred) 32.3±18.1 39.0±21.3 ns
Baseline 6MWT (m) 240±81 212±96 ns
Baseline sgrQ (points) 64.0±11.7 65.8±14.1 ns
∆FeV1 (%) 24.9±26.1 22.2±23.8 ns
∆VC (%) 17.4±21.9 12.0±21.1 ns
∆rV (%) -6.7±16.9 -8.8±18.6 ns
∆TlC (%) -0.1±8.0 -3.1±11.7 ns
∆Kco (%) 38.9±57.1 23.6±55.9 ns
∆6MWT (m) 8.0±45.3 58.8±69.6 0.014
∆sgrQ (points) -7.2±13.9 -11.8±13.7 ns
Notes: Data are presented as mean ± standard deviation. P-values were calculated for categorical variables using the chi-square test and Fisher’s exact test and for continuous 
variables using the Mann–Whitney U-test.
Abbreviations: INL, ipsilateral nontarget lobe; ns, not significant; BMI, body mass index; HI, heterogeneity index; RUL, right upper lobe; RLL, right lower lobe; LUL, left 
upper lobe; lll, left lower lobe; FeV1, forced expiratory volume in 1 second; VC, vital capacity; rV, residual volume; TlC, total lung capacity; Kco, diffusing capacity of the 
lung for carbon monoxide (corrected for lung volume); 6MWT, 6-minute walk test; sgrQ, st george’s respiratory Questionnaire; ∆, change from baseline to follow-up.
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Likewise, the distribution of patients into the four group 
combinations of low or high TL perfusion and low or high HI 
was not significantly different (P=0.58, Table S3). The same 
was observed for the groups of low and high INL perfusion 
and low or high HI (P=1.0, Table S3).
Comparing TL perfusion, INL perfusion, and HI to 
outcome parameters, low vs high TL perfusion was not 
associated with any outcome indices (Table S1). In contrast, 
patients with INL perfusion 14.7% demonstrated a higher 
increase in 6MWT than patients with INL perfusion below 
14.7% (P=0.014), while the other outcome parameters were 
similar for both groups (Table 1). Likewise, patients with 
HI 12.2% had a higher improvement in FEV
1
 than patients 
with HI ,12.2% (P=0.012), while the other outcome param-
eters were similar for both groups (Table 2).
To confirm these results, TL perfusion, INL perfu-
sion, and HI were tested for correlation with the outcome 
parameters. Likewise, no significant correlation was identi-
fied between TL perfusion and any change in clinical out-
come (Figure S1). Again, INL perfusion was significantly 
correlated only with changes in the 6MWT between baseline 
and follow-up (r=0.35, P=0.03; Figure 4A), and not with 
changes in TL volume (r=-0.05, P=not significant [ns]), 
FEV
1
 (r=0.01, P=ns), RV (r=-0.10, P=ns), VC (r=0.07, 
P=ns), Kco (r=-0.08, P=ns), and SGRQ (r=-0.11, P=ns; 
Figure S2). Similarly, HI demonstrated a significant correla-
tion only with changes in FEV
1
 (r=0.45, P=0.001; Figure 4B), 
but not with changes in TL volume (r=-0.09, P=ns), RV 
(r=-0.12, P=ns), VC (r=0.14, P=ns), SGRQ (r=-0.15, 
P=ns), Kco (r=-0.05, P=ns), and 6MWT (r=0.05, P=ns; 
Figure S3). Interestingly, improvement of 6MWT of 50.8 m 
among patients with high INH perfusion compared to low 
INL perfusion was independent of the HI (Figure 5A and C), 
and, likewise, improvement of FEV
1
 of 17.8% among patients 
with high HI compared to low HI was not associated with 
INL perfusion (Figure 5B and D).
Discussion
In this study, we found a significant correlation between high 
INL perfusion and larger improvement in the 6MWT and 
Table 2 Patient baseline characteristics and clinical outcome with respect to baseline hI
Parameters Homogeneous emphysema (,12.2% HI) Heterogeneous emphysema ($12.2% HI) P-value
n 27 27
Baseline hI 6.4±3.3 21.2±6.5 0.001
sex, n, (male/female) 15/12 16/11 ns
age (yr) 66.6±5.3 69.0±5.9 ns
BMI (kg/m2) 25.5±4.5 24.3±5.4 ns
smoking history (pack-yr) 48.7±25.9 47.2±15.3 ns
Treatment site ns
rUl 6 1
rll 3 1
lUl 5 7
lll 13 18
Baseline FeV1 (% pred) 26.6±7.3 25.7±6.9 ns
Baseline VC (% pred) 64.4±13.7 64.0±13.8 ns
Baseline rV (% pred) 215±31 215±36 ns
Baseline TlC (% pred) 121±13 121±11 ns
Baseline Kco (% pred) 31.4±16.7 37.9±22.4 ns
Baseline 6MWT (m) 232±77 215±96 ns
Baseline sgrQ (points) 64.1±14.4 66.8±11.7 ns
∆FeV1 (%) 14.9±19.9 32.7±27.3 0.012
∆VC (%) 14.9±23.3 16.7±23.8 ns
∆rV (%) -7.8±14.9 -7.8±20.0 ns
∆TlC (%) -1.7±9.5 -1.7±10.7 ns
∆Kco (%) 31.3±52.9 29.1±60.1 ns
∆6MWT (m) 32.8±73.9 38.2±50.8 ns
∆sgrQ (points) -9.8±14.6 -10.1±14.3 ns
Notes: Data are presented as mean ± standard deviation. P-values were calculated for categorical variables using the chi-square test and Fisher’s exact test and for continuous 
variables using the Mann–Whitney U-test.
Abbreviations: HI, heterogeneity index; ns, not significant; BMI, body mass index; RUL, right upper lobe; RLL, right lower lobe; LUL, left upper lobe; LLL, left lower 
lobe; FeV1, forced expiratory volume in 1 second; VC, vital capacity; rV, residual volume; TlC, total lung capacity; Kco, diffusing capacity of the lung for carbon monoxide 
(corrected for lung volume); 6MWT, 6-minute walk test; sgrQ, st george’s respiratory Questionnaire; ∆, change from baseline to follow-up.
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between a high HI and larger improvement in FEV
1
. Ana-
lyzing subgroups, patients with high INL perfusion (cutoff 
14.7%) benefited from a greater improvement of 50.8 m 
in the 6MWT compared to those with low INL perfusion, 
while patients with a heterogeneous emphysema distribution 
(cutoff 12.2% HI) showed a higher increase in FEV
1
 of 17.8% 
compared to those with low HI.
Important factors were recently characterized to predict 
the clinical success of ELVR. Several studies suggest that 
ELVR is an effective treatment option if complete lobar 
Figure 2 Clinical outcomes of patients after elVr with valves. 
Notes: The parameters were assessed prior to and 3 months after treatment. P-values were calculated using the Wilcoxon test. (A) TLV. TLV was quantified from computed 
tomograms before and after elVr using the MeVisPUlMO3D software. (B) FeV1. (C) rV. (D) VC. (E) sgrQ. (F) 6MWT. Data are presented as mean and standard deviation. 
numbers indicate relative change.
Abbreviations: elVr, endoscopic lung volume reduction; TlV, target lobe volume; FeV1, forced expiratory volume in 1 second; rV, residual volume; VC, vital capacity; 
sgrQ, st george’s respiratory Questionnaire; 6MWT, 6-minute walk test.
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Figure 4 Correlations between perfusion of the Inl, hI and outcome parameters.
Notes: P-values were calculated using the student’s t-test. (A) Correlation between Inl perfusion and change in ∆6MWT after elVr. (B) Correlation between hI and 
∆FeV1 after elVr.
Abbreviations: Inl, ipsilateral nontarget lobe; hI, heterogeneity index; 6MWT, 6-minute walk test; elVr, endoscopic lung volume reduction; FeV1, forced expiratory 
volume in 1 second; r, Pearson’s correlation coefficient; ∆, change from baseline to follow-up.
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occlusion with valves is achieved.2,8–10 In line, other studies 
have shown valve treatment to be less efficient, if valves were 
placed in both lungs without the goal of lobar occlusion.11,12 
A post hoc analysis of the US- and Euro-VENT studies 
identified a subset of patients who had no CV and who 
achieved higher lung volume reduction and greater clinical 
response.1,9 The importance of the absence of CV to the out-
come was recently confirmed by the BeLieVeR-HIFi study in 
a randomized, sham-controlled study design.2 Subsequently, 
it has become routine practice to assess interlobar CV by 
analysis of fissure integrity on high-resolution CT scan or 
by real-time endobronchial in vivo measurement with the 
Chartis system.3,4,8,14
This study suggests that INL lung perfusion sig-
nificantly predicts the improvement of the 6MWT after 
ELVR. Consequently, perfusion scintigraphy seems to be 
an important criterion for baseline evaluation of patients 
prior to ELVR. Among COPD patients, we observed a large 
variability of TL and INL perfusions ranging from very 
high to extreme low, which supports the concept of COPD 
heterogeneity.21,22 In this context, it is important to note that 
the perfusion of TL or INL is calculated as a percentage 
of the perfusion of the total lung. Therefore, a seemingly 
homogeneously perfused COPD lung might be severely 
impaired due to homogeneous parenchymal destructions of 
the lung. Similar to other authors, we found an association 
between perfusion and emphysema score (Figure S4).23 
Interestingly, however, we also identified severe hypoper-
fused regions irrespective of the emphysematic changes, 
suggesting other pulmonary vascular abnormalities such as 
local vascular inflammation with remodeling to be relevant 
to these COPD lungs.24,25
It remains unclear how perfusion affects improvements 
in the 6MWT after ELVR. The 6MWT is a predictor of 
mortality in patients with severe emphysema and has 
been established in the evaluation of COPD patients.26–28 
It reflects the exercise capacity of patients based on the 
pulmonary, cardiovascular, and muscular systems. Chung 
et al29 first examined perfusion in patients treated with 
ELVR and reported that perfusion decreased in the treated 
lung, while it increased in the contralateral lung. This was 
confirmed by other studies, which specified that after the 
treated lobe was reduced in volume, the perfusion and 
volume was redirected to the INL and to the contralateral 
lung.18,30,31 This interesting finding suggests that both the 
INL and contralateral lung take over functionality after 
development of an atelectasis of the TL, which explains 
the importance of the INL.32
However, while we did not find an effect of TL perfu-
sion on the 6MWT, a recent study by Argula et al17 reports a 
better 6MWT performance in patients with low TL perfusion. 
This may be due to the fact that we mostly treated the lower 
lobes of patients, which were already associated with less 
perfusion, while Argula et al17 mostly treated the upper lobes 
of patients. Moreover, Argula et al’s17 data also consisted of a 
slightly higher proportion of patients with heterogeneous lung 
emphysema in comparison to our study group. Nevertheless, 
high INL perfusion seems to be an indicator of a relatively 
healthier functional lobe, while low TL perfusion probably 
indicates a more damaged lobe. We hypothesize that the 
findings of improved 6MWT in low TL perfusion and high 
INL perfusion may together represent an optimal setting for 
ELVR: a more functional INL with high perfusion and a 
more damaged TL with low perfusion.
Recent studies suggest that each lung lobe contributes 
differently to the pulmonary function; the lower lobes dem-
onstrated a higher association to the FEV
1
 than the upper 
lobes.33,34 In this study, mostly the LLL was treated, which 
might be another explanation why the changes in lung func-
tion were greater than in previous studies like the VENT 
study. However, because the lower lobes in general, and 
especially the LLL, were treated more often in this cohort, 
we cannot evaluate this effect due to the small number of 
patients in whom the upper lobes were treated. A small study 
by Eberhardt et al35 found no difference for the treatment of 
upper vs lower lobes with valves. Nevertheless, future studies 
with an equal distribution of the TL are needed to test for a 
different outcome of ELVR for each specific TL. Moreover, 
the recent interesting studies by Matsuo et al33 and Kitano 
et al34 used the normal lobar volume and the collapsibility 
index as CT-derived indices to analyze lobar physiology 
and function. These indices might be useful in the future to 
evaluate lung lobes prior to ELVR.
Another important finding of this study is the correlation 
of improvement in FEV
1
 after ELVR to the baseline HI, sug-
gesting a greater improvement of FEV
1
 in patients with higher 
differences in the emphysema distribution between TL and 
the ipsilateral nontarget upper or lower lobe (middle lobes 
were not considered for HI calculations). There are several 
possible explanations for this observation: in lungs with het-
erogeneous emphysema, the TL consists of more bullae and 
cysts compared to the INL, while in homogeneous emphy-
sema, both are more evenly distributed. Because these bullae 
and cysts are the main contributors to the hyperinflation, 
ELVR of the TL in a high heterogeneity lung may lead to a 
more significant reduction hyperinflation and consequently 
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improve respiratory mechanics and air trapping. Moreover, 
compressed areas of the better-preserved adjacent lobes can 
reinflate to increase the surface of the lung to improve the 
gas exchange. This finding is in agreement with the North 
American VENT cohort reporting better clinical results in 
patients with heterogeneous compared to homogeneous 
emphysema.1 However, some other studies have not observed 
these associations of emphysema distribution and outcome 
changes;6,9,16 therefore, further studies are urgently needed 
for clarification. Currently, a prospective randomized trial is 
studying the effect of ELVR in patients with homogeneous 
and heterogeneous lung emphysema and no CV.36
A standardized definition of how to distinguish between 
heterogeneous and homogeneous lung emphysema is still 
lacking. In clinical routine and some other studies, het-
erogeneity is visually assessed on native CT scans,2,37,38 
which is observer dependent and therefore highly variable. 
Software-based quantification tools allow investigators to 
quantify precisely the severity of emphysema in the lobes. 
Some studies converted the quantified emphysema score to 
a Likert scale to determine the HI.39,40 This study used the 
definition of the VENT study, which defined the HI as the 
difference in emphysema score between the target and 
the ipsilateral adjacent lobe.1 The median HI was 15% in the 
VENT study, which was used to split patients into low and 
high HI subgroups. The 15% median was suggested as an 
arbitrary cutoff marker for homogeneous and heterogeneous 
emphysema. Applying the same method, we split the patients 
into a low and high heterogeneity group at the median HI in 
this study. The median of 12.2% suggests a higher fraction 
of patients with homogeneous emphysema compared to the 
VENT. Nevertheless, there was a significant correlation 
between HI and FEV
1
 improvement, indicating the predictive 
value of the HI regardless of a cutoff.
It is interesting to note that baseline HI was the main 
contributor of FEV
1
 improvement, while INL perfusion was 
almost only associated with increases of 6MWT after ELVR. 
This suggess that morphologic changes of emphysematous 
damaged lobes are more likely to influence breathing mechan-
ics, while INL perfusion shows higher correlations to exercise 
capacity. On the basis of the findings for INL perfusion and 
HI, we distinguished four COPD patient groups according 
to their baseline perfusion and HI in the TL: 1) patients 
with HI and high INL perfusion who were more likely to 
improve in FEV
1
 and 6MWT; 2) patients with high HI and 
low INL perfusion who demonstrated better improvements 
in FEV
1
, but less in 6MWT; 3) patients with low HI and high 
INL perfusion who showed less improvement in FEV
1
 but 
higher 6MWT changes; and 4) patients with low HI and low 
INL who were less likely to respond in FEV
1
 and 6MWT. 
Especially the last patient group might be a new subgroup 
to show limited response to ELVR even though this patient 
group fulfilled the other factors relevant to clinical success 
(significant hyperinflation in PFT, negative CV in TL, and 
complete lobar occlusion with valves).
Several possible limitations of this study should be 
considered. The division of planar perfusion scintigrams 
into thirds is only a rough estimation of lung perfusion and 
reduces the accuracy of the data. This limitation could be 
addressed in the future by software-based quantification tools 
for SPECT, which analyze the perfusion for each anatomical 
lung lobe. These tools showed impressive initial results, but 
are not yet widely used.41,42 Consequently, future studies 
should be performed using software-based quantification 
tools for SPECT to reassess the role of pulmonary perfusion 
for ELVR patient selection. However, because perfusion 
scintigraphy is already widely used prior to ELVR, the find-
ings of this study are still highly relevant despite the limita-
tions of planar perfusion imaging until SPECT is established 
in the clinical routine.
This is a retrospective analysis without blinding or 
patient randomization, and baseline characteristics are 
not evenly distributed, and so a selection bias cannot be 
excluded. CT scan and perfusion scintigraphy were also used 
for TL selection, which might bias the results. Therefore, 
prospective studies with well-matched and larger cohorts 
are urgently needed to confirm these results. Correlation 
analyses need careful interpretation due to the possible 
role of confounding variables, which might not have been 
considered. The only data that were evaluated were those in 
patients’ files, as a consequence of the retrospective study 
design. We used the medians to discriminate between low 
and high INL perfusion and low and high HI; however, there 
might be better cutoff values for discriminating between the 
patient subgroups. To better understand the improvements 
in exercise capacity, other exercise tests, such as spiroer-
gometry, are needed.
In summary, patient selection remains critical in ELVR 
because it bears the risk of severe complications.43 Baseline 
HI and lobe perfusion may help to identify patients who 
benefit most from ELVR treatment. While patients with 
heterogeneous emphysema are more likely to profit from 
improved breathing mechanics, patients with high INL 
perfusion might benefit from improved exercise capacity. 
These predictors could be helpful in selecting both the patient 
and the TL for ELVR.
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Technical details of perfusion scintigraphy
Ventilation and perfusion were assessed using a hybrid 
dual-head Siemens Symbia TruePoint T6 SPECT/CT system 
(Siemens Medical Solutions, Erlangen, Germany), which 
has a crystal thickness of 9.5 mm, and a 53.3 cm axial by 
38.7 cm diameter single-photon emission computed tomog-
raphy (SPECT) field of view. The scans were performed 
following a 1-day standard protocol: 128×128 acquisition 
matrix, zoom 1.0, pixel size 4.8 mm, and noncircular orbit 
(autocontour) with 30 projections over 180° (continuous 
acquisition). A low-energy high-resolution collimator was 
used with dual-energy windowing, and a lower scatter 
energy window (10% width) for scatter estimation. Thirty 
samples, each of 15 seconds duration, were used for both 
the ventilation and the perfusion study. The total acquisi-
tion time was approximately 20 minutes. The seated patient 
inhaled about 60 MBq Tc-99m Technegas (Tema 10,000, 
Cyclomedica GmbH, Salzgitter, Germany) and the ventila-
tion SPECT was performed. After the ventilation SPECT 
was performed, 100–120 MBq of 99 mTc-labeled human 
albumin macroaggregates (Mallinckrodt Medical BV, 
Petten, the Netherlands) were slowly injected intravenously 
while the patient took deep breaths. Perfusion tomography 
was then performed on the patient who was lying down. 
Only posterior-to-anterior planar views were used for further 
analyses due to the lack of software-based quantification 
tools for SPECT.
This study protocol was already described by the 
coauthors in another study using the same patients and 
procedure.1
Table S1 Patient baseline characteristics and clinical outcome with respect to baseline Tl perfusion
Parameters Below median TL perfusion (,8.11%) Above median TL perfusion ($8.11%) P-value
n 27 27
Baseline Tl perfusion 4.8±1.7 11.9±2.7 0.001
sex, n, (male/female) 14/13 17/10 ns
age (yr) 69.8±5.7 66.6±5.0 0.027
BMI (kg/m2) 25.1±5.1 25.5±4.8 ns
smoking history (pack-yr) 42.3±15.9 53.6±24.0 ns
hI ,12.2% 11 14 ns
hI $12.2% 14 12
Treatment site 0.001
rUl 2 5
rll 0 4
lUl 2 11
lll 23 7
Baseline FeV1 (% pred) 27.4±6.5 25.8 ±7.3 ns
Baseline VC (% pred) 65.3±11.9 63.6±14.7 ns
Baseline rV (% pred) 217±40 217±36 ns
Baseline TlC (% pred) 123±17 120±11 ns
Baseline Kco (% pred) 43.4±23.0 28.9±13.9 0.042
Baseline 6MWT (m) 239±80 212±98 ns
Baseline sgrQ (points) 63.0±12.4 66.7±13.0 ns
∆FeV1 (%) 19.8±22.4 27.3±26.8 ns
∆VC (%) 14.1±23.2 15.2±20.0 ns
∆rV (%) -9.8±17.9 -5.6±17.4 ns
∆TlC (%) -3.2±11.2 -0.04±8.6 ns
∆Kco (%) 17.4±52.6 42.1±57.8 ns
∆6MWT (m) 26.4±47.2 38.8±76.0 ns
∆sgrQ (points) -7.1±13.8 -11.9±13.8 ns
Notes: Data are presented as mean ± standard deviation. P-values were calculated for categorical variables using the chi-square test and Fisher’s exact test, and for 
continuous variables using the Mann–Whitney U-test.
Abbreviations: TL perfusion, baseline percentage perfusion of TL; TL, target lobe; ns, not significant; BMI, body mass index; HI, heterogeneity index; RUL, right upper lobe; 
rll, right lower lobe; lUl, left upper lobe; lll, left lower lobe; FeV1, forced expiratory volume in 1 second; VC, vital capacity; rV, residual volume; TlC, total lung capacity; 
Kco, diffusing capacity of the lung for carbon monoxide; sgrQ, st george’s respiratory Questionnaire; 6MWT, 6-minute walk test distance; ∆, change from baseline to 
follow-up.
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lung perfusion and emphysema distribution
Table S2 Clinical outcome after elVr
Parameters Baseline Follow-up Absolute change Relative change (%) P-value
FeV1 (% pred) 26.2±6.9 32.0±9.3 5.8±6.5 23.8±24.9 0.001
VC (% pred) 64.0±13.4 72.8±15.3 8.8±12.1 15.9±23.2 0.001
rV (% pred) 219±38 200±46 -18.7±37.1 -8.0±17.3 0.001
TlC (% pred) 123±14 120±17 -2.4±12.2 -1.8±9.9 0.129
Kco (% pred) 34.6±19.8 35.2±14.8 4.9±13.4 31.1±55.0 0.013
6MWT (m) 222±89 257±103 34.6±62.3 28.0±84.4 0.001
sgrQ (points) 65.7±13.3 55.4±16.6 -10.1±14.0 -15.4±20.4 0.001
Notes: Data are presented as mean ± standard deviation. numbers may not sum up to total due to rounding. P-values were calculated using the Wilcoxon test.
Abbreviations: elVr, endoscopic lung volume reduction; FeV1, forced expiratory volume in 1 second; rV, residual volume; VC, vital capacity; TlC, total lung capacity; 
Kco, diffusing capacity of the lung for carbon monoxide; sgrQ, st george’s respiratory Questionnaire; 6MWT, 6-minute walk test distance.
Table S3 Patient groups with respect to perfusion and emphysema heterogeneity
Low TL perfusion (,8.11%) High TL perfusion ($8.11%) P-value
hI ,12.2% 11 14 0.579
hI $12.2% 14 12
Low INL perfusion (,14.7%) High INL perfusion ($14.7%) P-value
hI ,12.2% 12 13 1.0
hI $12.2% 13 13
Notes: numbers indicate numbers of patients in each group. P-values were calculated using the chi-square test. 
Abbreviations: Tl, target lobe; hI, heterogeneity index; Inl, ipsilateral nontarget lobe.
Figure S1 Correlations with baseline percentage perfusion of the Tl.
Notes: P-values were calculated using the student’s t-test. (A) Correlation between Tl perfusion and ∆TlV. (B) Correlation between Tl perfusion and ∆FeV1. 
(C) Correlation between Tl perfusion and ∆rV. (D) Correlation between Tl perfusion and ∆VC. (E) Correlation between Tl perfusion and ∆sgrQ. (F) Correlation 
between Tl perfusion and ∆6MWT.
Abbreviations: Tl, target lobe; ∆, change from baseline to follow-up; TlV, target lobe volume; r, Pearson’s correlation coefficient; ns, not significant; FEV1, forced expiratory 
volume in 1 second; rV, residual volume; sgrQ, st george’s respiratory Questionnaire; 6MWT, 6-minute walk test distance; VC, vital capacity.
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Figure S2 Correlations with baseline percentage perfusion of the Inl.
Notes: P-values were calculated using the student’s t-test. (A) Correlation between Inl perfusion and ∆TlV. (B) Correlation between Inl perfusion and ∆FeV1. 
(C) Correlation between Inl perfusion and ∆rV. (D) Correlation between Inl perfusion and ∆VC. (E) Correlation between Inl perfusion and ∆sgrQ. (F) Correlation 
between Inl perfusion and ∆6MWT.
Abbreviations: Inl, ipsilateral nontarget lobe; ∆, change from baseline to follow-up; TlV, target lobe volume; r, Pearson’s correlation coefficient; ns, not significant; FEV1, 
forced expiratory volume in 1 second; rV, residual volume; sgrQ, st george’s respiratory Questionnaire; 6MWT, 6-minute walk test distance; VC, vital capacity.
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Figure S3 Correlations with baseline hI.
Notes: hI is the difference in emphysema scores between the potential Tl and the ipsilateral lobe. P-values were calculated using the student’s t-test. (A) Correlation 
between hI and ∆TlV. (B) Correlation between hI and ∆FeV1. (C) Correlation between hI and ∆rV. (D) Correlation between HI and ∆VC. (E) Correlation between hI 
and ∆sgrQ. (F) Correlation between hI and ∆6MWT.
Abbreviations: hI, heterogeneity index; Tl, target lobe; ∆, change from baseline to follow-up; TlV, target lobe volume; r, Pearson’s correlation coefficient; ns, not significant; 
FeV1, forced expiratory volume in 1 second; rV, residual volume; sgrQ, st george’s respiratory Questionnaire; 6MWT, 6-minute walk test distance; VC, vital capacity.
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lung perfusion and emphysema distribution
Figure S4 Correlations between baseline perfusion and es for each lung lobe.
Notes: P-values were calculated using the student’s t-test. (A) Correlation between baseline perfusion and es for the rUl. (B) Correlation between baseline perfusion and 
es for the lUl. (C) Correlation between baseline perfusion and es for the rll. (D) Correlation between baseline perfusion and es for the lll.
Abbreviations: es, emphysema score; rUl, right upper lobe; lUl, left upper lobe; rll, right lower lobe; lll, left lower lobe; r, Pearson’s correlation coefficient.
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